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“Most often the entire valve appears normal; . . . There is little to fix, yet
the valve leaks. . . . the valve is structurally normal; it need not be
replaced, but currently we do not know how to fix it . . . . “ 
—L. Henry Edmunds, Jr, 19971
The pair of articles in this issue of the Journal by Gillinov,2 Grossi,3 andtheir colleagues revisits an old and unanswered question: Is it better torepair or replace the leaking mitral valve in patients with coronaryartery disease that has caused ischemic mitral regurgitation (IMR)?These two articles bring contemporary clarity to this dilemma and rep-resent a major step forward, but they do not answer all our questions.
This controversy was reignited in 1995 by Lawrence Cohn and his colleagues4
from the Brigham, who reported that the outcome of patients with IMR undergoing
mitral repair or mitral valve replacement (MVR) plus coronary artery bypass graft-
ing (CABG) was not so much dependent on the choice of operative procedure per
se, but more on the underlying pathophysiology of the IMR and the patient’s clini-
cal presentation. This enlightened certain surgeons who had already convinced
themselves that repair was better, but also reminded us that the prognosis for these
sick patients was markedly suboptimal. Patients with IMR have morphologically
normal mitral leaflets and subvalvular apparatus, but the valve can leak badly.
Previously, surgeons had not talked a lot about IMR, perhaps because none of our
surgical results were particularly good. Subsequently, we learned conclusively in
the multicenter SAVE (Survival and Ventricular Enlargement) trial that even a mild
degree of mitral regurgitation (MR) portended a substantial excessive risk of car-
diovascular mortality within 5 years after acute myocardial infarction,5 even in
patients who did not have any overt signs of congestive heart failure at the time of
study entry. These data reinforced the results of prior observational studies of
patients with IMR, both those treated medically after a myocardial infarction and
those undergoing CABG or percutaneous transluminal coronary angioplasty.
Earlier retrospective surgical studies included patients with many different types
of mitral valve disease, including those with prolapse found to have incidental coro-
nary artery disease, which only confounded the issue. One beauty of the two arti-
cles published in this issue of the Journal is that only patients with IMR caused by
coronary artery disease were investigated; that is, these are “clean” studies. Second,
these papers used strict pathophysiologic criteria to classify the patients with
respect to the mechanism of IMR. Even though different descriptive terms were
used, an important message is that we distinguish between “functional IMR,”
infarcted but not ruptured papillary muscle, and ruptured papillary muscle. The vast
majority is represented by patients with functional IMR, which can be due to one
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of the following reasons: (1) simple annular dilatation (sec-
ondary to left ventricular [LV] enlargement), which causes
incomplete mitral leaflet coaptation associated with
Carpentier type I (normal) leaflet motion; (2) local LV
remodeling with papillary muscle displacement producing
apical tethering or tenting of the leaflets (with Carpentier
type III-b restricted systolic leaflet motion); or (3) both
mechanisms. Importantly, exhaustive analyses from the
Mayo Clinic echocardiography laboratory6,7 have provided
a great amount of insight into the mechanisms of IMR and
its clinical impact. Thanks to these investigators, we can
now reliably measure leaflet tenting area and tenting height
quantitatively from transthoracic echocardiograms in
patients with LV dysfunction and IMR or functional MR, as
well as estimate the effective regurgitant orifice.6 Larger
effective regurgitant orifice, or more leak, was directly and
independently predicted by excess leaflet tenting and loss of
systolic annular contraction, but it was not related to the
degree of LV dysfunction. Adverse prognostic conse-
quences were also clearly documented, moreover, as
medium-term survival for patients with IMR and LV dys-
function was strongly and independently related to calcu-
lated effective regurgitant orifice, even after statistical
adjustment for all other variables.7 Recently, Otsuji and
associates,8 working in Vlahakes’ and Levine’s laboratory at
the Massachusetts General Hospital, experimenting with
short-term canine and long-term sheep models and 3-
dimensional echocardiographic imaging, also contributed
new information concerning the mechanisms of IMR result-
ing from LV local remodeling.
Now that we better understand what we are talking about
(and can actually measure it!), surgeons should be more
aggressive and not ignore substantial degrees of IMR at the
time of CABG. This policy should also apply to patients
undergoing percutaneous coronary revascularization with
percutaneous transluminal coronary angioplasty and stent-
ing to optimize their prognosis, but such is unlikely since we
do not live in a utopia and the interventional cardiologists
have not figured out quite yet how to repair leaking mitral
valves in the cardiac catheterization laboratory.
But, does one do a ring annuloplasty or a more reliable
chordal-preserving MVR? As the authors of the two accom-
panying articles declare,2,3 the answer is not a simple one.
Historically, we have been handicapped by comparing very
different cohorts of patients in attempting to assess whether
repair offers a better outcome than does MVR. The patients
receiving these two procedures were very dissimilar and not
directly comparable, truly an apples versus oranges situa-
tion. Fallacious conclusions resulted from such compar-
isons. In the absence of randomized trials, which are
probably unrealistic, this handicap persists as demonstrated
in both accompanying papers2,3; but, new statistical tools
are now available that can help neutralize the inherent
patient selection bias that plagues such retrospective studies.
In the Gillinov analysis of 482 patients,2 Blackstone used
propensity score analysis and other sophisticated statistical
methods to generate quintiles of patients undergoing either
repair or MVR that were relatively well matched to answer
the question whether one procedure is better than the other,
and, if so, in which particular patient. This approach identi-
fied subsets of patients (unbalanced in numbers) that were
reasonably well balanced in terms of risk factors. Bootstrap
resampling (so-called “bagging”) was also used to validate
the results of the model and confirm that the results were
generalizable. This important paper (together with the
appendixes) deserves to be read carefully and repeatedly; it
is remarkable for its clarity of prose (even though it is writ-
ten in a tongue that I affectionately call “Gene-speak.” A
massive amount of effort was invested, including Gillinov
reviewing all available original echocardiographic tapes to
reclassify the patient population. About 70% of patients—
but not the sickest patients—were believed to benefit from
repair. The amount of relative benefit of repair in terms of
survival was less or actually erased if a thoracic artery was
not used for CABG, a lateral LV wall motion abnormality
was present, or the IMR jet was “complex.” The sickest
patients did equally poorly with either procedure, and in cer-
tain cases MVR was in fact associated with better predicted
survival. Overall 5-year survival was still disappointing,
regardless of whether the valve was repaired or replaced.
Propensity score analysis was also explored by Grossi
and associates,3 who evaluated 223 patients with IMR; but,
the New York University statisticians concluded that the
marked imbalance in numbers of patients undergoing one
procedure or another within the quintiles was such that the
propensity score models did not provide an adequate fit to
the data. Therefore, propensity score adjustments were not
used. Instead, the New York University group did multiple
convoluted layers of multivariable analyses to adjust for the
confounding effects of functional disability (New York
Heart Association class), presence of angina, and particular
operation performed, followed by separate Cox modeling
within each of the two surgical groups. The nuances of this
arcane statistical debate are best left to the professional bio-
statisticians, whom I invite to air their differences in public
so as to educate the rest of us. Perhaps propensity score
analysis worked in the Cleveland Clinic series because it
comprised more than twice the number of patients as did the
New York University series. Fortunately, several invited
papers concerning these statistical topics will be forthcom-
ing soon in the Journal. Suffice it to say, the patients who
underwent mitral repair at New York University were not as
sick as those who required MVR (as was also the case in the
Gillinov report2); medium-term survival was suboptimal but
roughly equivalent between the two types of procedures.
Certain subsets of patients were identified who appeared to
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do better if they could undergo repair. This lack of pro-
nounced difference in survival between the repair and the
MVR groups is similar to the conclusions just reported by
Calafiore and colleagues9 in patients with functional MR
and incomplete mitral leaflet coaptation due to dilated idio-
pathic cardiomyopathy (n = 12) or IMR due to ischemic car-
diomyopathy (n = 7), but certain differences beg
amplification. In the Italian experience,9 recurrence of MR
was frequent after repair if what Calafiore called mitral
valve coaptation depth (which is equivalent to the Mayo
term “coaptation height”6 and indicative of apical leaflet
tenting) was 11 mm or greater; this stands to reason as no
matter how small one makes the mitral anulus, this maneu-
ver cannot recreate competent leaflet coaptation if one or
both leaflets are extensively apically tethered because of
papillary muscle displacement. If one wants to save the
valve in these cases, more radical repair procedures are
required, such as external LV plication or buttressing,8
realignment of papillary muscle geometry inside the ventri-
cle, leaflet patch extension as described by Dobre, Koul, and
Rojer,10 or perhaps an Alfieri stitch. Second, the mitral
reparative procedures performed in Calafiore’s series
included pericardial strip annuloplasty or a modified De
Vega–type or Paneth-type continuous suture annuloplasty,
which have been abandoned by most surgeons. In the
Cleveland Clinic2 and the New York University3 articles,
both of these techniques were much less effective than
implantation of a synthetic mitral annuloplasty band or ring.
Despite my enthusiasm to see these two articles finally
published and my appreciation of their clinical value, one
must still be a little circumspect.
1. Neither study2,3 included a control group of patients
that had comparable degrees of IMR but underwent
CABG only; hence, what Donald Glower calls the
“straw man hypothesis” exists, again.
2. Two other important end-points were not evaluated in
either study: (a) the impact of mitral repair versus MVR
on LV systolic function over time and (b) the adequacy
of the repair as assessed by serial echocardiographic
surveillance. Although the incidence of reoperation
after repair was low, this could be misleading for two
reasons: (I) many patients could have had recurrent
IMR but been so sick they were not considered suitable
candidates for reoperation and (II) the death rates were
so high that relatively few patients remained at risk for
structural valve deterioration of the repair beyond 2 to
3 years. These two essential end-points should be the
focus of future investigations.
3. Finally, despite whatever procedure was performed, the
5-year survival was still not much better than 50%. This
indicates that successful revascularization and correction
of the IMR does relatively little in terms of ameliorating
the ravages of previous LV infarction and ischemia.
The Bottom Line
Patients with IMR represent a heterogeneous group that has
a soberingly dismal medium-term prognosis because of
underlying LV systolic dysfunction. As Steven Bolling is
wont to say: “IMR is a ventricular disease, not a valvular
disease.” We now recognize that ignoring an important
degree of IMR at the time of CABG is not prudent because
it will only limit the potential functional benefit to be
attained from operation and compound the patient’s poor
life expectancy. One exception to this policy would be the
uncommon situation where an inferior LV wall motion
abnormality causing IMR is known preoperatively to be due
to reversible ischemia involving viable myocardium, such
that revascularization alone has a high likelihood of correct-
ing the IMR.
Valve repair with an undersized annuloplasty ring works
satisfactorily in most cases of functional IMR, but the sur-
geon needs to pay keen attention in interpreting the genesis
and direction of the MR leak. If simple annular dilatation
resulting in incomplete mitral leaflet coaptation and associ-
ated with Carpentier type I leaflet motion is the main culprit
and the leak is centrally directed straight back into the
atrium or slightly posteriorly directed (due to “pseudo-pro-
lapse” of the anterior leaflet, which reflects restriction of the
posterior leaflet), then it is likely that simple ring annulo-
plasty will work well and will be fairly durable; conversely,
if the pattern of the IMR leak is complex, or substantial api-
cal tenting of the leaflets is identified (Carpentier type III-b
restricted systolic leaflet motion), or a lateral wall infarct is
present, then simple ring annuloplasty may not be the most
prudent course of action. The most important surgical goal
in repairing the valve is to reduce and fix the mitral annular
dimension in the anterior-posterior (or “septal-lateral” in
anatomic terms) axis, not the commissure-commissure axis.
Although both partial or complete and flexible or rigid rings
perform satisfactorily,2,3 in theory this goal may best be
accomplished in patients with IMR by using stiffer rings, for
example, Carpentier-Edwards Classic (not Physio)
(Edwards Lifesciences, Irvine, Calif), Carbomedics
AnnuloFlo (Sulzer Carbomedics, Austin, Tex), or the newly
approved Medtronic CG Future Band (a partial, semirigid
ring, Medtronic Heart Valve Division, Minneapolis, Minn),
developed by Colvin, Galloway, and Grossi. This is despite
the fact that the first two types of ring completely abolish
annular dynamic motion and in contrast to patients with
mitral prolapse, in whom a flexible, partial (posterior only)
band is preferred by me and many others.
Surgeons today frequently are taking a more aggressive
approach and adding a mitral ring during coronary revascu-
larization if substantial IMR is present. Does this mean that
all patients undergoing CABG who have more than mild
MR should receive concomitant mitral annuloplasty?
Probably not. Such enhances the risk of air embolism and
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prolongs cardiopulmonary bypass time, which is likely to
increase the already high operative mortality risk because
these patients invariably have poor LV systolic func-
tion.2,3,9,11 This judgment decision needs to be based on the
severity and the mechanism of the IMR as assessed on the
preoperative echocardiogram under stress or ambulatory
hemodynamic conditions; assessment intraoperatively by
transesophageal echocardiography is unreliable and often
misleading because of the LV pressure and volume unload-
ing effects of general anesthesia. Given our current excellent
methods of myocardial protection, making an error of com-
mission rather than one of omission with respect to ring
annuloplasty is perhaps the most sensible course of action
when one is uncertain; however, again, the nature and mech-
anism of the IMR leak needs to be fully appreciated.
Without a doubt, a role still remains for MVR, especially
if all anterior and posterior leaflet chordae are preserved. This
reasonable alternative may be preferable for surgeons who do
not do many dozens of mitral repair procedures each year.
Other circumstances in which a quick and dependable MVR
may be the better side of valor when facing functional IMR
include the very sickest patients, those with a complex MR
leak or a lateral LV wall motion abnormality, and patients
with considerable apical leaflet tenting. Additionally, individ-
uals with an infarcted or ruptured papillary muscle and very
ill patients presenting on an emergency basis after an acute
myocardial infarction probably are best served by chordal-
sparing MVR. Given the markedly limited life expectancy of
patients with IMR, it does not make any sense to use a
mechanical prosthesis for MVR, irrespective of the patient’s
age; a tissue valve is indicated because very few of these
patients will actually live long enough to sustain structural
deterioration of their bioprosthesis. Further, saving all the
subvalvular apparatus is less technically demanding and
fraught with fewer potential postoperative valve-related com-
plications if a bioprosthesis is used.
I respect the cardiac surgeons at these two institutions,
and I salute them and their statistical coworkers for their
honesty and candor. Thanks to a huge amount of hard work
on their part, our knowledge base concerning the surgical
treatment of patients with IMR is more complete after pub-
lication of these two articles.
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